State Street’s MoonLake Immunotherapeutics MLTX Stock Holding History

State Street’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.7M	Buy	87,166 +30,676	+54%	+$556K	﹤0.01%	3375
2026 Q1	$1.05M	Buy	56,490 +5,517	+11%	+$91.4K	﹤0.01%	3477
2025 Q4	$672K	Sell	50,973 -1,913	-4%	-$22.6K	﹤0.01%	3609
2025 Q3	$379K	Sell	52,886 -11,678	-18%	-$609K	﹤0.01%	3724
2025 Q2	$3.05M	Sell	64,564 -28,833	-31%	-$1.17M	﹤0.01%	3157
2025 Q1	$3.65M	Buy	93,397 +1,852	+2%	+$79.8K	﹤0.01%	3005
2024 Q4	$4.96M	Buy	91,545 +3,908	+4%	+$200K	﹤0.01%	2985
2024 Q3	$4.42M	Buy	87,637 +42,980	+96%	+$2.01M	﹤0.01%	3023
2024 Q2	$1.96M	Sell	44,657 -704	-2%	-$29.8K	﹤0.01%	3325
2024 Q1	$2.28M	Buy	45,361 +15,020	+50%	+$815K	﹤0.01%	3237
2023 Q4	$1.83M	Buy	30,341 +9,541	+46%	+$492K	﹤0.01%	3340
2023 Q3	$1.19M	Buy	+20,800	New	+$1.15M	﹤0.01%	3486

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street's MLTX Position: Q2 2026 in Review

State Street increased its MoonLake Immunotherapeutics (MLTX) stake by 54% in Q2 2026, buying an estimated $556K and bringing the position to 87,166 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3375.

State Street first reported a position in MLTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $4.96M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

State Street held 87,166 shares of MoonLake Immunotherapeutics worth $1.7M as of Q2 2026.
State Street bought 30,676 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $556K.
MoonLake Immunotherapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3375 holding.
State Street first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 12 quarters since.
State Street's MoonLake Immunotherapeutics position peaked at $4.96M in Q4 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.